Related Experiment Videos
Angioplasty for long-term treatment of patients with Budd-Chiari syndrome
L G Martin1, J M Henderson, W J Millikan
1Department of Radiology, Emory University Hospital, Atlanta, GA 30322.
Insights
Percutaneous balloon angioplasty safely manages Budd-Chiari syndrome by controlling portal hypertension. This interventional radiology technique offers long-term benefits for patients until natural venous pathways develop.
Area of Science:
- Interventional Radiology
- Hepatology
- Vascular Medicine
Background:
- Budd-Chiari syndrome is characterized by hepatic venous outflow obstruction, leading to portal hypertension and liver damage.
- Radiologic intervention aims to restore venous outflow and prevent hepatocellular injury.
Purpose of the Study:
- To evaluate the safety and efficacy of percutaneous balloon angioplasty in managing Budd-Chiari syndrome.
- To assess the long-term outcomes of angioplasty in patients with this condition.
Main Methods:
- Six patients with Budd-Chiari syndrome underwent percutaneous balloon angioplasty.
- Procedures targeted hepatic veins, inferior vena cava, or shunt anastomoses.
- Patients were followed for an average of 43 months, with clinical and hemodynamic assessments.
Main Results:
- Clinical and hemodynamic improvement was observed after each angioplasty session.
- Multiple dilatations (average 3.2) were necessary due to restenosis.
- Five of six patients experienced long-term benefit, despite some cases of caval occlusion or restenosis.
Conclusions:
- Percutaneous balloon angioplasty is a safe and effective adjunctive therapy for Budd-Chiari syndrome.
- The procedure moderates disease severity, facilitating the development of collateral venous pathways.
- Long-term management often requires repeated angioplasty interventions.
Abstract:
The goal of radiologic intervention in patients with Budd-Chiari syndrome is to control portal hypertension and prevent further hepatocellular damage until collateral hepatic venous outflow channels can develop. Percutaneous balloon angioplasty was used to treat six patients with this syndrome who were followed up for an average of 43 months (range, 12-92 months). Standard interventional radiologic techniques were used to dilate the hepatic veins (two patients), inferior vena cava (three patients), and proximal anastomosis of a mesoatrial shunt (one patient). Angioplasty was the only invasive treatment in three patients, whereas the remaining three patients had previous portosystemic shunts. Clinical and hemodynamic improvement occurred after each angioplasty. Multiple dilatations were required in all patients (average, 3.2; range, 2-5) because of restenosis at the angioplasty site and ongoing hepatocyte necrosis shown by biopsy. Long-term benefit occurred in five patients despite ultimate caval occlusion in two patients and restenosis in one patient. One patient who was almost free of symptoms for 36 months developed gastrointestinal bleeding caused by portal hypertension. This experience suggests that balloon angioplasty is a safe and effective treatment for patients with Budd-Chiari syndrome. The therapy is not definitive, but serves to moderate the severity of the disease until collateral venous pathways develop. Multiple angioplasties are required for the long-term care of these patients.